StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Cubicin (daptomycin, legacy) by Quarter

Cubicin (daptomycin, legacy) — International sales ($M) ($M)

QuarterlyAnnual

Merck Cubicin (daptomycin, legacy): $26M in Q4 2020, down 27.8% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2020
26
Period ended Dec 31, 2020
Change on a year earlier
-27.8%
36 in Q4 2019
History
17 quarters
Since Q4 2016
Sources
13
Documents cited below

Where the Q4 2020 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2021-02-25) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCubicin (daptomycin, legacy) — International sales ($M) ($M)Year on yearSource
Q4 2020Dec 31, 202026-27.8%Form 10-K (filed 2021-02-25) ↗
Q3 2020Sep 30, 202028-26.3%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 202021-53.3%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 202031-32.6%Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q4 2019Dec 31, 201936-7.7%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2019Sep 30, 201938-5.0%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2019Jun 30, 201945-2.2%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2019Mar 31, 201946-9.8%Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q4 2018Dec 31, 201839-25.0%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2018Sep 30, 201840-20.0%Form 8-K (tm1921023d1_ex99-1.htm, filed 2019-10-29) ↗
Q2 2018Jun 30, 201846-8.0%Form 8-K (a19-15283_1ex99d1.htm, filed 2019-07-30) ↗
Q1 2018Mar 31, 201851+24.4%Form 8-K (a19-8996_1ex99d1.htm, filed 2019-04-30) ↗
Q4 2017Dec 31, 201752+44.4%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2017Sep 30, 201750–Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗
Q2 2017Jun 30, 201750–Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗
Q1 2017Mar 31, 201741–Form 8-K (a18-12417_1ex99d1.htm, filed 2018-05-01) ↗

Breakdown

What makes up cubicin (daptomycin, legacy)

Cite this data

StockData. (2026). Merck Cubicin (daptomycin, legacy) ($M), quarterly Q4 2016–Q4 2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-cubicin-intl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.